New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology

X Zhou, D Xu, M Li, X Zeng - Expert Opinion on Investigational …, 2024 - Taylor & Francis
Introduction Sjögren's syndrome is a heterogeneous autoimmune condition that impairs
quality of life because of dryness, fatigue, pain, and systemic involvements. Current …

Sjögren's syndrome: shedding light on emerging and key drug targets

D Ridgewell, N Thalayasingam… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Sjögren's syndrome (SS) is an immune-mediated inflammatory condition
characterized by sicca syndrome, musculoskeletal pain, and fatigue. Extra-glandular …

The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: a systematic review of trials

R Felten, F Scher, J Sibilia, JE Gottenberg… - Autoimmunity Reviews, 2019 - Elsevier
To date, no immunomodulatory drug has proved efficacious in primary Sjögren's syndrome
(pSS). In pSS, difficulties in drug efficacy assessment is related to the large spectrum of …

Emerging biologic frontiers for Sjogren's syndrome: Unveiling novel approaches with emphasis on extra glandular pathology

XX Li, M Maitiyaer, Q Tan, WH Huang, Y Liu… - Frontiers in …, 2024 - frontiersin.org
Primary Sjögren's Syndrome (pSS) is a complex autoimmune disorder characterized by
exocrine gland dysfunction, leading to dry eyes and mouth. Despite growing interest in …

An update of targeted therapeutic options for primary Sjögren syndrome: current status and future development

S Retamozo, A Sisó-Almirall… - Expert Opinion on …, 2021 - Taylor & Francis
ABSTRACT Introduction: Primary Sjögren syndrome (pSS) is a systemic autoimmune
disease that may affect 3 in 1,000 people within the general population. The therapeutic …

Future treatments for Sjögren's syndrome

JO Pers, A Saraux - La Presse Médicale, 2016 - Elsevier
Primary Sjögren's syndrome (pSS) is a systemic multiorgan autoimmune disease that runs a
chronic progressive course. The recently developed treat-to-target paradigm involves …

Biologics in sjogren's syndrome

E Price - Handbook of Biologics for Rheumatological Disorders, 2022 - Springer
Sjögren's syndrome (SS) is a chronic, autoimmune disease whose serological and
histological characteristics suggest would be a good candidate for Biologic therapy. There …

Why do drug treatments fail in Sjögren's disease? Considerations for treatment, trial design and interpretation of clinical efficacy

S Arends, GM Verstappen, L de Wolff… - Expert review of …, 2023 - Taylor & Francis
Introduction Despite ongoing efforts to develop effective therapeutics, no disease-modifying
drugs have been officially licensed for the indication of Sjögren's disease (SjD). This is partly …

Emerging biological therapies in primary Sjögren's syndrome

M Ramos-Casals, P Brito-Zerón - Rheumatology, 2007 - academic.oup.com
Sjögren's syndrome (SS) is a systemic autoimmune disease that mainly affects the exocrine
glands and usually presents as persistent dryness of the mouth and eyes. SS primarily …

The future of targeted treatment of primary Sjögren's syndrome: a focus on extra-glandular pathology

W Zeng, X Zhou, S Yu, R Liu, CWN Quek, H Yu… - International Journal of …, 2022 - mdpi.com
Primary Sjögren's syndrome (pSS) is a chronic, systemic autoimmune disease defined by
exocrine gland hypofunction resulting in dry eyes and dry mouth. Despite increasing interest …